REGENXBIO Inc.
RGNX· Nasdaq
RGNXREGENXBIO Inc.
Filed Mar 1, 2022 · 10-K · 60 days after period end · 0001564590-22-008055
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $398.66M | $21.45M | $11.77M | $40.78M |
| Net Income | $294.02M | -$46.24M | -$26.46M | $4.31M |
| EPS Diluted | — | -$1.24 | -$0.72 | $0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Mar 1, 2022 · 60 d after period end
